Fitch agrees that weight gain is likely to occur when someone stops taking a GLP-1 medication, so she recommends talking to your healthcare provider about more affordable options
Prescriptions to young people for two GLP-1 medications semaglutide and liraglutide (Saxenda) jumped 700% between 2022 and 2024
Both medications can affect appetite, cardiovascular parameters, and gastrointestinal function, so individualised riskbenefit evaluation and regular review are essential
The unregulated nature of the research peptide market means product quality varies dramatically between suppliers
Over 72 weeks, participants without type 2 diabetes achieved the following weight loss results : 5 mg dose: 16.0% average body weight reduction 10 mg dose: 21.4% average body weight reduction 15 mg dose: 22.5% average body weight reduction Placebo: 2.4% average body weight reduction At the highest dose, 92.7% of participants achieved at least 5% weight loss, 84.4% achieved at least 10%, 73.6% achieved at least 15%, 56.1% achieved at least 20%, and 38.7% achieved at least 25% weight loss
There are three primary enemies of a lyophilized peptide
